Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADC TherapeuticsADCT -6.67%41 Days Payable is 182.63 as of Mar. 2026, which is 86% below its 10-year median of 1,350.70. GuruFocus rates ADCT with a GF Score™ of 41/100 and a GF Value™ of $2.09 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 925 Drug Manufacturers companies, ADC Therapeutics ranks better than 94.59% on this metric.
The historical rank and industry rank for ADC Therapeutics's Days Payable or its related term are showing as below:
ADCT'
s Days Payable Range Over the Past 10 Years
Min: 474.59 Med: 1350.7 Max: 2274.24
Current: 474.59
During the past 10 years, ADC Therapeutics's highest Days Payable was 2274.24. The lowest was 474.59. And the median was 1350.70.
ADCT's Days Payable is ranked better than 94.59% of 925
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs ADCT: 474.59
ADC Therapeutics's Days Payable
declined
from Mar. 2025 (744.28) to Mar. 2026 (182.63).
It may suggest that ADC Therapeuticsaccelerated paying its suppliers.
ADC Therapeutics Days Payable Related Terms
ADC Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for ADC Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ADC Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADC Therapeutics (ADCT) has a Days Payable of 182.63 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ADC Therapeutics and its competitors. This is 86% below median its historical median of 1,350.70. Over the past decade, ADC Therapeutics' Days Payable has ranged from 474.59 to 2,274.24. According to the industry distribution chart, ADC Therapeutics ranks #50 out of 925 companies in the Drug Manufacturers industry, placing it in the top 5.4%.
Is ADC Therapeutics' Days Payable too high?
ADC Therapeutics' current Days Payable of 182.63 is 86% below median its 10-year median of 1,350.70. Over the past 10 years, this metric has ranged from a low of 474.59 to a high of 2,274.24. The Drug Manufacturers industry median Days Payable is 90.38. ADC Therapeutics' value of 182.63 is 102.1% above this industry median. Based on the distribution chart, ADC Therapeutics ranks #50 out of 925 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, ADC Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' Days Payable compare to GNLX and VXRT?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #50 out of 925 companies for Days Payable. This places ADC Therapeutics in the top 5% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. ADC Therapeutics' value of 182.63 is 102.1% above this benchmark. Historically, ADC Therapeutics' own Days Payable has ranged from 474.59 to 2,274.24 over the past decade. While the company's 10-year median is 1,350.70 vs. the industry median of 90.38, ADC Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADC Therapeutics's current Days Payable of 182.63 is 102.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ADC Therapeutics and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADC Therapeutics's current Days Payable is 182.63, which is 86% below median its own 10-year median of 1,350.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.09, compared to a current price of $1.26 — trading 39.7% below its estimated fair value. The current Days Payable is 182.63, which is 86% below median its 10-year median of 1,350.70 and 102.1% above the Drug Manufacturers industry median of 90.38. ADC Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current Days Payable is 182.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.26 is trading 39.7% below its estimated GF Value™ of $2.09.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
Days Payable: 182.63 (86% below median its 10-year median of 1,350.70)
GF Value™: $2.09 vs. price of $1.26 (39.7% below fair value)
Industry Position: 102.1% above the Drug Manufacturers median (#50 of 925)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score
Get the complete analysis for ADCT
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
